Page 1

Viking Therapeutics InvestorRoom Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP - 1 / GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens 22 % Placebo - Adjusted Weight Loss Reported at Week 33 Following Weekly Dosing of VK2735 at 17.5 mg ; No Plateau Observed Results Demonstrate Viability of Monthly and Every Other Week Dosing Regimens for Maintaining Weight Loss ; Increasing Options for Adherence to Treatment Up to 97 % of Weight Loss Maintained Following Transition to Every Other Week Dosing for Three Months Up to 90 % of Weight Loss Maintained Following Transition to Monthly Dosing for Three Months Excellent Tolerability Observed During Maintenance Dosing with GI Adverse Event Rates Similar to Placebo Conference Call Scheduled for 8:00 a.m . ET Today SAN DIEGO , Sept. 22 , 2026 / PRNewswire / -- Viking Therapeutics , Inc. ( " Viking " ) ( NASDAQ : VKTX ) , a clinical - stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders , today announced positive top - line results from the company's maintenance study of VK2735 , the company's dual agonist of the glucagon - like peptide 1 ( GLP - 1 ) and glucose - dependent insulinotropic polypeptide ( GIP ) receptors . In this study , subjects receiving subcutaneous VK2735 demonstrated superior weight maintenance following the transition to less frequent dosing regimens compared with subjects transitioned to placebo . In addition , VK2735 demonstrated an encouraging safety and tolerability profile during the 12 - week maintenance dosing period , with observed rates of GI - related adverse events comparable to placebo . The company believes these results further differentiate VK2735 by demonstrating compelling weight loss maintenance via new long - term dosing regimens , including monthly and every - other - week administration . VK2735 is being developed in both subcutaneous and oral formulations for the potential treatment of various metabolic disorders such as obesity . The company plans to explore oral maintenance dosing regimens in an upcoming part 2 to the current study . VIKING THERAPEUTICS " The results of our innovative maintenance dosing study continue to demonstrate the significance of VK2735's unique and differentiated half - life and PK profile , which appear to enable an effective new approach to achieving and maintaining the weight loss goals of patients living with obesity , " said Brian Lian , Ph.D. , chief executive officer of Viking . " We believe this dose - ranging study clearly demonstrated the potential viability of novel , extended dosing approaches for maintenance following induction with an incretin - based therapy . We believe flexible dosing approaches will provide both patients and their providers with new options for improving long - term adherence to therapy and sustained weight management , both of which are essential to realizing the most critical benefits of weight loss , such as improved cardiovascular